Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

42 MAJOR PRODUCTS Prescription Pharmaceuticals Aricept Alzheimer’s disease treatment Azeptin Antiallergy agent Iomeron Non-ionic contrast medium Inhibace Long-acting ACE inhibitor Infree Analgesic/anti-inflammatory agent Glakay Osteoporosis treatment Glucagon G Novo Genetically engineered glucagon preparation Cleactor Thrombolytic agent Selbex Gastritis/gastric ulcer medication Nitorol-R Long-acting isosorbide dinitrate preparation Neuquinon Metabolic cardiotonic Aciphex/Pariet Proton pump inhibitor Myonal Muscle relaxant Methycobal Peripheral neuropathy therapy Juvela Nicotinate Microcirculation activator Rulid Long-acting macrolide antibiotic Consumer Health Care Products Saclon S For upset stomach associated with pain and heartburn Sahne Cream Medicated skin care cream Seabond Denture adhesive Skainar S for Rhinitis Medicine for rhinitis Chocola AD For relief of dry eyes and supplement of vitamins A & D Chocola BB For Vitamin B2 supplement, stomatitis & dermatitis Chocola BB Pure Active type Vitamin B2 preparation with Vitamin B6,B1,C Chocola BB Fresh Vitamin B2 preparation Chocola EC Natural type vitamin E plus vitamin C granules Travelmin Motion sickness remedy Nabolin Active-type vitamin B12 preparation Bayclear Plus Medication for Athlete’s foot Breathe Right Nasal Strips Ubiten S Ubidecarenone (Coenzyme Q 10) preparation Juvelux 300 Natural vitamin E preparation Eisai Annual Report 2001 Diagnostic Products Albusure For detection of microalbumin Eitest CA/RF For determination of antiagalactosyl IgG antibodies Eitest IgGRF For determination of IgG rheumatoidfactor Eitest KL-6 For determination of sialylated carbohydrate antigen KL-6 Eitest PIVKA-II For determination of abnormal prothrombin (PIVKA-II) Clinisearch CA/RF For detection of antiagalatosyl IgG antibodies Thrombotest Owren For monitoring blood coagulation activities New Eitest-ATL For detection of anti HTLV-1 antibody Picolumi AFP For determination of α-fetoprotein(AFP) Picolumi CA/RF For determination of antiagalatosyl IgG antibodies Picolumi KL-6 For determination of sialylated carbohydrate antigen KL-6 Picolumi For determination of abnormal PIVKA-II prothrombin (PIVKA-II) Hepaplastintest For monitoring liver functions and blood coagulation activities Chemicals and Food Additives Ajitonica Flavoring agent Amicanon Food preservative D-mixed Natural antioxidant Tocopherols Concentrate Lysozyme Hydrochloride Xylose Sweetening material Synthetic vitamin E and derivatives Natural vitamin E and derivatives Animal Health Products Astop Fifth-generation cationic disinfectant Anxin Broad-spectrum antibiotic Infec New quinolone synthetic antibiotic Chitofine Chitosan wound dressing Trimix Multivitamin aqueous solution for poultry farming Pacoma Virucidal and bactericidal disinfectant for veterinary use Mycobuster Inactivated vaccine for mycoplasmosis of swine Juvela Food 100 Vitamin E preparation for veterinary use Pharmaceutical Production System and Machines AIM Automatic Inspection Machine EIS Eisai inspection System MWS High-Frequency Wave Continuous Sterilizer BSI Black Spot Inspection Machine AAPM Automatic Ampoule Packing Machine
BOARD OF DIRECTORS, CORPORATE OFFICERS, AND CORPORATE AUDITORS (As of June 28, 2001) Board of Directors Chairman Yuji Naito President and Chief Executive Officer Haruo Naito Representative Director Hiromasa Nakai Directors Aishin Shinoda Hideaki Matsui Yoji Takaoka Yasuhiro Mita Ichiro Kataoka (Professor Emeritus, Keio University) Shigehiko Yoshino (Counselor of Asahi Bank Ltd.) Corporate Auditors Nobuo Eda Yukio Akimoto Teruo Osawa Mitsuo Minami (Certified Public Accountant, Professor, Faculty of Business Administration, Bunkyo Women's University) Katsuro Tanaka (Counsellor-at-law and Representative Partner, TMI Associates) Nobuo Eda, Mitsuo Minami and Katsuro Tanaka are external auditors as stipulated by Act 18-1 related to the exception of the commercial code for audits. Eisai Annual Report 2001 Deputy President Hiromasa Nakai Corporate Officers Executive Vice President Aishin Shinoda Research and Development Senior Vice Presidents Tadashi Nakai Japan Prescription Drug Business Hideaki Matsui Management Planning, Human Resources, Emerging Business and International Affairs Yoji Takaoka Prescription Drug Division Yasuhiro Mita Production and Logistics Vice Presidents Hiroshi Yamauchi Research and Development Matsuo Ohara Prescription Drug Division and Director of Kansai-Hokuriku Area Kenji Toda Product Quality and GMP Compliance Akiyoshi Uchiyama Regulatory Affairs and Medical Information Makoto Shiina Business Development Masao Jimbo Finance, Information Systems, and Japan Network Companies Kozaburo Inoue Prescription Drug Division and Director of Tokyo Area Hideaki Hayano Consumer Health Product Division Shintaro Kataoka Production and Logistics and General Manager of Kawashima Industrial Complex Nobuo Deguchi Corporate Ethics, Public Relations and Legal Affairs Hiroyuki Mitsui Corporate Communications, Environmental Affairs and General Affairs 43
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13 and 14: working together to develop antican
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17 and 18: Consumer Health Care Products The c
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?